🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Well done Ray and team! An overdue and important tinker!!

INASL-SAASL Consensus Statements on NAFLD Name Change to MAFLD jcehepatology.com/article/S0973-… AASLD INASL APASL News ACG American Gastroenterological Association (AGA)

It’s here. And it is wonderful: AASLD practice guidance on nonalcoholic fatty liver disease - PubMed. Well done!! And kudos to the first author, our very own Maru Rinella!! 🍾👏 ⁦UChicago Digestive Diseases⁩ ⁦Maru Rinella MD⁩ #livertwitter ⁦⁦Rohit Loomba⁩ pubmed.ncbi.nlm.nih.gov/36727674/

It has been an absolute privilege to work with Ahmad Anouti, MD An amazing researcher, clinician, patient advocate and person His amazing journey is a must read for anyone involved in medicine. Helps remind us why we do this work, be it research or clinical utsouthwestern.edu/ctplus/stories…

These are a great way to stay current with the most exciting new publications in our field - highly recommend!

Important topic + great investigators and speakers = Think differently by the conclusion of the conference. See you there!! Banff quite a nice place too.

Mine too!

With OCA a new casualty of a palpably capricious FDA review process, not only is an effective agent lost and the field chilled but the costs of unscientific adcom decisions will be baked into Rx costs. FDA review shouldn’t resemble a ride in the Titan sub. #LiverTwitter #FDA

Over 10,000 lives are lost to liver disease in the UK each year. On Monday’s show, Dr Dr Xand van Tulleken 🏳️‍🌈 joins us to talk about the condition and the lifestyle changes we can make to reduce our risk of getting the disease. 📧 Do you have a question for Dr Xand? Get in touch now.

It’s true! #NAFLDNomenclature is now known as #MASLDNomenclature. MASLD (pronunciation: Ma-zuld) encompasses patients who have hepatic steatosis w/at least 1 (out of 5) cardiometabolic risk factors. Read the joint publication at bit.ly/3XvnXSb #LiverTwitter

The guard has changed. Thank you and farewell NAFLD, NASH and MAFLD. Welcome SLD, MASLD and MASH! Well done and thank you to the Delphi panel and the 60+ medical societies who have already endorsed. AASLD EASLnews Maru Rinella MD Phil Newsome Global Liver Institute Fatty Liver Foundation

When is the last time this many organizations agreed on something? This is an impressive turnout in support of the new nomenclature to replace NAFLD/NASH. Start using MASLD and MASH! #LiverTwitter @aasldtweets #MASLDNomenclature ALEH EASLnews

MASLD-tov!! #livertwitter ⁦AASLD⁩ ⁦EASLnews⁩ ⁦ALEH⁩ ⁦Mazen Noureddin, MD, MHSc⁩ ⁦Naim Alkhouri⁩ ⁦Jeffrey V. Lazarus⁩ ⁦Elliot Tapper⁩ ⁦Juan Pablo (JP) Arab, MD ⁩ ⁦Ramon Bataller⁩ Phil Newsome

Some thoughts on the first in person EASL / ILC meeting since pandemic: 👉Attendance for major meetings (AASLD, EASL) ~60% of peak pre-COVID. Will be $$ challenges. 👉In person far superior to Zoom etc. 👉Liver science is accelerating (NASH, HCC and HBV on 🔥) 👉🙏🏻👏 #EASL

Elliot Tapper The #MASLDnomenclature article in HEPATOLOGY Journal journals.lww.com/hep/Fulltext/9… is now ranked 16th of >8500 articles tracked by Altmetric in Hepatology and is in the top 50k all time: altmetric.com/details/150489… Keep sharing and expand the community of practice: journals.lww.com/hep/Fulltext/9…

In this meta-analysis of individual patient data, liver biopsy performed the same as FIB-4, fibroscan liver stiffness and NAFLD fibrosis score in predicting clinical outcomes up to 10 yrs in pts with NAFLD Time to abandon liver biopsies! ➡ Use FIB-4! doi.org/10.1016/S2468-…

Keystone MASH and Fibrosis: Molecular Phenotypes to Precision Therapeutics has kicked off with Arun Sanyal delivering the Keynote opener. A masterful synthesis of a doyen’s knowledge!

Some early Keystone insights: Weight loss is less of a driver of MASLD histology than we thought. FFA are the major source of hepatic lipids (not DNL) and we are what our parents ate, at least epigenetically. 🤔

New fave pic. On the L is Stefano Romeo, 1st author on PNPLA3 in MASLD Nature paper. On the R is Greg Tesz, lead scientist at Pfizer for first PNPLA3 Rx in human studies. From genetic assn to clinical trial. I ❤️ it! Keystone Symposia are a lot of work. But worth it! 💪 2gether.

The ILC at EASL winds down. Best ever. This was our Last Supper.